



The First Asia-Pacific Myeloid Forum (APMF) 2025
24 – 25 May 2025 | HKUMed Academic Building, Hong Kong

Addressing Treatment Needs and Advancing Care in the Asia-Pacific Region

Tentative Programme

Day 1: 24 May 2025 (Saturday)

Time	Topic	Speaker
12:00 - 13:00	Registration, Lunch and Exhibition Viewing	
Lunch Symposium 1 (Sponsored by BMS)		
Moderator: Prof. Harry Gill		
13:00 - 14:00	Paradigm Shift in the Management of Myelodysplastic Syndrome (MDS)	Dr. Ing Soo Tiong (Australia)
14:00 - 14:10	Opening Remarks	Prof. Yok-Lam Kwong (Hong Kong)
Session 1: Acute Promyelocytic Leukaemia (APL)		
Moderator: Prof. Yok-Lam Kwong		
14:15 - 14:35	Preventing Early Deaths in APL	Prof. Harry Gill (Hong Kong)
14:35 - 14:55	Oral Arsenic Trioxide/ATRA/Ascorbic Acid as the New Standard-of-care for APL	Prof. Harry Gill (Hong Kong)
14:55 - 15:10	Q & A	
15:10 - 15:40	Tea Break and Exhibition Viewing	
Session 2: Acute Myeloid Leukaemia (AML)		
Moderator: Prof. Harry Gill and Prof. Hsin-An Hou		
15:40 - 16:00	Genomic Landscape and Risk Stratification in AML	Prof. Harry Gill (Hong Kong)
16:00 - 16:20	Frontline Management of the “Fit” AML	Prof. Hee-Je Kim (Korea)
16:20 - 16:40	Frontline Management of the “Unfit” AML: Optimizing Initial Treatment for AML - from Present to Future	Dr. Chun-Yew Fong (Australia)
16:40 - 17:00	Maintenance Therapy in AML	Prof. Harry Gill (Hong Kong)
17:00 - 17:20	Optimizing Treatment for Patients with Relapsed/Refractory FLT3+ AML	Dr. Richard Dillon (UK)
17:20 - 17:40	The <i>TP53</i> -mutated MDS/AML	Prof. Harry Gill (Hong Kong)
17:40 - 18:00	Panel Discussion	



The First Asia-Pacific Myeloid Forum (APMF) 2025
24 – 25 May 2025 | HKUMed Academic Building, Hong Kong

Addressing Treatment Needs and Advancing Care in the Asia-Pacific Region

Tentative Programme

Day 2: 25 May 2025 (Sunday)

Time	Topic	Speaker
08:30 - 09:00	Registration	
Session 3: Myelodysplastic Neoplasm (MDS)		
Moderator: Prof. Harry Gill and Prof. Hsin-An Hou		
09:00 - 09:20	Clonal Haematopoiesis and Its Implications	Dr. Than Hein (Singapore)
09:20 - 09:40	Germline Predisposition to Myeloid Neoplasm	Dr. Than Hein (Singapore)
09:40 - 10:00	Genomic Landscape and Risk Stratification in MDS	Prof. Hsin-An Hou (Taiwan)
10:00 - 10:20	Panel Discussion	
10:20 - 10:50	Tea Break and Exhibition Viewing	
10:50 - 11:10	Management of Lower-risk MDS and VEXAS Syndrome	Dr. Tony Wu (Hong Kong)
11:10 - 11:30	Management of High-risk MDS	Dr. Melissa Ooi (Singapore)
11:30 - 11:50	Panel Discussion	
Lunch Symposium 2 (Sponsored by PharmaEssentia)		
Moderator: Prof. Harry Gill		
11:50 - 12:50	Clinical Impact of Genetic Alterations and Variant Allele Frequency on MPN	Prof. Hsin-An Hou (Taiwan)
12:50 - 13:50	Lunch and Exhibition Viewing	
Session 4: Myeloproliferative Neoplasm (MPN)		
Moderator: Prof. Harry Gill and Dr. Garret Leung		
13:50 - 14:10	Molecular Risk Stratification in MPN	Prof. Chieh-Lee Wong (Malaysia)
14:10 - 14:30	JAK Inhibitors for PV and ET	Prof. Mary Frances McMullin (UK)
14:30 - 14:50	Interferon-alfa for PV, ET, and Pre-PMF	Dr. Winnie Teo (Singapore)
14:50 - 15:10	Panel Discussion	
15:10 - 15:40	Tea Break and Exhibition Viewing	
15:40 - 16:10	Advanced Management Strategies and Clinical Evidence in Myelofibrosis	Prof. Giuseppe A. Palumbo (Italy)
16:10 - 16:30	Management of Cytopenic Myelofibrosis (MF)	Prof. Yeow-Tee Goh (Singapore)
16:30 - 16:50	Allogeneic HSCT for MF – When and How?	Dr. Garret Leung (Hong Kong)
16:50 - 17:10	Panel Discussion	
Session 5: Chronic Myeloid Leukaemia (CML)		
Moderator: Prof. Harry Gill and Prof. Yeow Tee Goh		
17:10 - 17:30	Frontline Management of CML	Dr. Takeshi Kondo (Japan)
17:30 - 17:50	Advances in the Treatment of CML	Prof. Charles Chuah (Singapore)
17:50 - 18:05	Panel Discussion	
18:05 - 18:15	Closing Remarks	Prof. Harry Gill